Low-dose emicizumab versus low-dose factor VIII secondary prophylaxis for noninhibitor hemophilia A patients with severe bleeding phenotype

Nuchanan Kessakorn, M.D.
King Chulalongkorn Memorial Hospital
Bangkok, Thailand

Resource constrained settings experience a financial burden for standard regimens of subcutaneous administration of emicizumab. Nuchanan Kessakorn, M.D., and the team discuss the clinical impact and pharmacokinetic profile of low-dose emicizumab prophylaxis after switching from low-dose FVIII prophylaxis in Thai noninhibitor HA patients. This presentation discusses results of 15 eligible subjects and the regimen of low-dose emicizumab compared with low-dose FVIII prophylaxis potentially helping address previously unmet needs in HA care among low-to-middle-income countries.